Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers (PANTHEoN)

NCT04892875 is registered in ClinicalTrials.gov with Jennifer Choe as lead sponsor.

NCT NCT04892875
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04892875 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers (PANTHEoN)
Lead sponsor
Jennifer Choe
Phase
Phase 1
Overall status
Withdrawn
Start date
December 31, 2023
Completion date
December 31, 2026
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer, hypopharynx cancer, hypopharynx squamous cell carcinoma, larynx cancer, oral cavity cancer, oral cavity squamous cell carcinoma, oropharynx cancer, oropharynx squamous cell carcinoma, pharynx cancer, squamous cell carcinoma of head and neck